<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d354">
    <sentence id="DDI-DrugBank.d354.s0" text="Tizoxanide is highly bound to plasma protein ( 99.9%).">
        <entity id="DDI-DrugBank.d354.s0.e0" charOffset="0-9"
            type="drug" text="Tizoxanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s1" text="Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).">
        <entity id="DDI-DrugBank.d354.s1.e0" charOffset="53-64"
            type="drug" text="nitazoxanide"/>
        <entity id="DDI-DrugBank.d354.s1.e1" charOffset="207-214"
            type="drug" text="warfarin"/>
        <pair id="DDI-DrugBank.d354.s1.p0" e1="DDI-DrugBank.d354.s1.e0"
            e2="DDI-DrugBank.d354.s1.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s2" text="In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d354.s2.e0" charOffset="51-60"
            type="drug" text="tizoxanide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d354.s3" text="Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.">
        <entity id="DDI-DrugBank.d354.s3.e0" charOffset="135-146"
            type="drug" text="nitazoxanide"/>
    </sentence>
</document>
